Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | RORC | P51449 | 3/20 | 0.38 |
| ▸ | DHODH | Q02127 | 1/20 | 0.38 |
| ▸ | MAPK10 | P53779 | 6/20 | 0.38 |
| ▸ | MAPK8 | P45983 | 5/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | CCR3 | P51677 | 3/20 | 0.36 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.36 |
| ▸ | RXRB | P28702 | 3/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.35 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3205108 | 1.00 | NPC1 (0.39) | NPC1RAB9ASMN1; SMN2RORCDHODH | |
| SCHEMBL3201367 | 0.93 | RORC (0.41) | NPC1RAB9ASMN1; SMN2RORCDHODH | |
| SCHEMBL3203598 | 0.93 | RORC (0.41) | NPC1RAB9ASMN1; SMN2RORCDHODH | |
| SCHEMBL5073015 | 0.93 | RORC (0.41) | NPC1RAB9ASMN1; SMN2RORCDHODH | |
| SCHEMBL3204702 | 0.93 | RORC (0.41) | NPC1RAB9ASMN1; SMN2RORCDHODH | |
| SCHEMBL3191043 | 0.89 | RORC (0.46) | NPC1RAB9ASMN1; SMN2RORCDHODH | |
| SCHEMBL3204623 | 0.89 | RORC (0.46) | NPC1RAB9ASMN1; SMN2RORCDHODH | |
| SCHEMBL3210356 | 0.88 | RORC (0.40) | NPC1RAB9ASMN1; SMN2RORCDHODH | |
| SCHEMBL3200383 | 0.86 | NPC1 (0.38) | NPC1RAB9ASMN1; SMN2RORCDHODH | |
| SCHEMBL3196777 | 0.85 | RORC (0.41) | NPC1RAB9ASMN1; SMN2RORCDHODH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070161617-A1 | Certain chemical entities, compositions and methods | CYTOKINETICS, INC. | 2007-07-12 | — | — | US | claimed |
| US-8871768-B2 | Certain chemical entities, compositions and methods | CYTOKINETICS, INC. (US) | 2014-10-28 | — | — | US | disclosed |
| US-20130324549-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | CYTOKINETICS, INC. (US) | 2013-12-05 | — | — | US | disclosed |
| US-8445495-B2 | Certain Chemical entities, compositions and methods | CYTOKINETICS, INC. (US) | 2013-05-21 | — | — | US | disclosed |
| US-20100029680-A1 | Certain Chemical Entities, Compositions and Methods | CYTOKINETICS, INC. | 2010-02-04 | — | — | US | disclosed |
| US-20070161617-A1 | Certain chemical entities, compositions and methods | CYTOKINETICS, INC. | 2007-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161617-A1 | Certain chemical entities, compositions and methods | TNNI3, TNNT2, MYLK2 | NPC1 4691/4885RAB9A 3170/4885SMN1; SMN2 1596/4885 |
| US-20130324549-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | TNNI3, TNNT2, MYLK2 | NPC1 4691/4885RAB9A 3170/4885SMN1; SMN2 1596/4885 |
| US-20100029680-A1 | Certain Chemical Entities, Compositions and Methods | TNNI3, TNNT2, MYLK2 | NPC1 4691/4885RAB9A 3170/4885SMN1; SMN2 1596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.